Mark R. Albertini, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Mark Albertini is an associate professor (with tenure) of medicine at the University of Wisconsin (UW). Dr. Albertini is a nationally known melanoma researcher who has led treatment efforts for patients with metastatic melanoma at the University of Wisconsin Carbone Cancer Center since he joined the faculty in 1993. Dr. Albertini established the UW Carbone Cancer Center Comprehensive Melanoma Clinic in September 1994 and is the leader of the UW Carbone Cancer Center Melanoma Disease-Oriented working group. Dr. Albertini has been awarded the Professionalism Award by the UW Department of Medicine Housestaff and has been selected for listing by the Best Doctors in America organization. Dr. Albertini has also served as Chief of Oncology at the William S. Middleton Memorial Veterans Hospital since January 2003.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
UW Comprehensive Cancer Center
University of Wisconsin Hospital and Clinics, Madison, WI
University of Wisconsin Hospital and Clinics, Madison, WI
University of Vermont College of Medicine, Burlington, VT, 1984
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Programs & Conditions
The overall goal of Dr. Mark Albertini's research program is to provide an understanding of the immunobiology of human malignant melanoma as a means to develop effective treatment and monitoring strategies for patients with this disease. This goal is pursued with clinical and laboratory studies involving melanoma patients and with preclinical model systems to direct subsequent clinical studies. Dr. Albertini has been a mentor for clinical trainees with an interest in the care of melanoma patients, and Dr. Albertini has provided focused melanoma translational laboratory training to predoctoral and postdoctoral trainees in his research laboratory. Dr. Albertini has been a member of the Melanoma Committee in the Eastern Cooperative Oncology Group since 1994.
Albertini MR Ranheim EA Zuleger CL Sondel PM Hank JA Bridges A Newton MA McFarland T Collins J Clements E Henry MB Neuman HB Weber S Whalen G Galili U .
Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunol Immunother. 2016 May 20;
[PubMed ID: 27207605]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH .
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract. 2015 Dec;21(6):416-24
[PubMed ID: 24986793]
Carvajal RD Sosman JA Quevedo JF Milhem MM Joshua AM Kudchadkar RR Linette GP Gajewski TF Lutzky J Lawson DH Lao CD Flynn PJ Albertini MR Sato T Lewis K Doyle A Ancell K Panageas KS Bluth M Hedvat C Erinjeri J Ambrosini G Marr B Abramson DH Dickson MA Wolchok JD Chapman PB Schwartz GK .
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Jun 18;311(23):2397-405
[PubMed ID: 24938562]
Pei Q Zuleger CL Macklin MD Albertini MR Newton MA .
A conditional predictive p-value to compare a multinomial with an overdispersed multinomial in the analysis of T-cell populations. Biostatistics. 2014 Jan;15(1):129-39
[PubMed ID: 24096387]
Bhatia N Xiao TZ Rosenthal KA Siddiqui IA Thiyagarajan S Smart B Meng Q Zuleger CL Mukhtar H Kenney SC Albertini MR Jack Longley B .
MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. J Invest Dermatol. 2013 Mar;133(3):759-67
[PubMed ID: 23096706]
Albertini MR Hank JA Gadbaw B Kostlevy J Haldeman J Schalch H Gan J Kim K Eickhoff J Gillies SD Sondel PM .
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother. 2012 Dec;61(12):2261-71
[PubMed ID: 22678096]
Zuleger CL Albertini MR .
OMIP-008: measurement of Th1 and Th2 cytokine polyfunctionality of human T cells. Cytometry A. 2012 Jun;81(6):450-2
[PubMed ID: 22431369]
Hank JA Gan J Ryu H Ostendorf A Stauder MC Sternberg A Albertini M Lo KM Gillies SD Eickhoff J Sondel PM .
Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res. 2009 Sep 15;15(18):5923-30
[PubMed ID: 19737959]
Yamane BH Hank JA Albertini MR Sondel PM .
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000
[PubMed ID: 19548853]
Albertini MR Macklin MD Zuleger CL Newton MA Judice SA Albertini RJ .
Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients. Environ Mol Mutagen. 2008 Dec;49(9):676-87
[PubMed ID: 18712786]
Dubovsky JA Albertini MR McNeel DG .
MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. J Immunother. 2007 Oct;30(7):675-83
[PubMed ID: 17893560]
Neal ZC Bates MK Albertini MR Herweijer H .
Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity. Mol Ther. 2007 Feb;15(2):422-30
[PubMed ID: 17235322]
Cassaday RD Sondel PM King DM Macklin MD Gan J Warner TF Zuleger CL Bridges AJ Schalch HG Kim KM Hank JA Mahvi DM Albertini MR .
A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):540-9
[PubMed ID: 17255276]
Kanjo T Albertini M Weber S .
Long-term disease-free survival after adrenalectomy for isolated colorectal metastases. Asian J Surg. 2006 Oct;29(4):291-3
[PubMed ID: 17098665]
Choi BS Sondel PM Hank JA Schalch H Gan J King DM Kendra K Mahvi D Lee LY Kim K Albertini MR .
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul;55(7):761-74
[PubMed ID: 16187086]
Osenga KL Hank JA Albertini MR Gan J Sternberg AG Eickhoff J Seeger RC Matthay KK Reynolds CP Twist C Krailo M Adamson PC Reisfeld RA Gillies SD Sondel PM .
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006 Mar 15;12(6):1750-9
[PubMed ID: 16551859]
Walker L Schalch H King DM Dietrich L Eastman M Kwak M Kim K Albertini MR .
Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res. 2005 Oct;15(5):453-9
[PubMed ID: 16179874]
Albertini MR Hank JA Sondel PM .
Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma. Cancer Chemother Biol Response Modif. 2005;22:789-97
[PubMed ID: 16110641]
King DM Albertini MR Schalch H Hank JA Gan J Surfus J Mahvi D Schiller JH Warner T Kim K Eickhoff J Kendra K Reisfeld R Gillies SD Sondel P .
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol. 2004 Nov 15;22(22):4463-73
[PubMed ID: 15483010]
Voss CY Albertini MR Malter JS .
Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine. Transfus Med Rev. 2004 Jul;18(3):189-202
[PubMed ID: 15248169]